dalteparin has been researched along with Morbid Obesity in 59 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| " There is no standard venous thromboembolism (VTE) prophylaxis for both dosing and duration of anticoagulation following laparoscopic sleeve gastrectomy." | 3.01 | Adding a Preoperative Dose of LMWH may Decrease VTE Following Bariatric Surgery. ( Abdelsalam, AM; Aisha, HAA; ElAnsary, AMSE; Elfergany, HM; Nassef, SA; Salman, MA, 2021) |
| "Enoxaparin dosing recommendations for morbidly obese patients are lacking." | 2.90 | Evaluation of Treatment-Dose Enoxaparin in Acutely Ill Morbidly Obese Patients at an Academic Medical Center: A Randomized Clinical Trial. ( Alexander, BR; Curry, MA; Evans, KS; Kempton, CL; LaFollette, JA; Tran, RH, 2019) |
| "The pharmacokinetic properties of enoxaparin may lead to supratherapeutic antifactor Xa (anti-Xa) levels and increased bleeding when standard treatment doses are used in patients with morbid obesity." | 2.80 | Evaluation and Pharmacokinetics of Treatment Dose Enoxaparin in Hospitalized Patients With Morbid Obesity. ( Chandler, WL; Liebl, PH; Muntz, JE; Putney, DR; Thompson-Moore, NR; Wanat, MA, 2015) |
| " In order to guide dosing in this patient group, a pharmacodynamics model is developed for nadroparin in morbidly obese and non-obese patients using anti-Xa levels as an endpoint, thereby characterizing the influence of excessive body weight on different pharmacodynamic model parameters." | 2.80 | Population pharmacodynamic model for low molecular weight heparin nadroparin in morbidly obese and non-obese patients using anti-Xa levels as endpoint. ( Diepstraten, J; Hackeng, CM; Janssen, EJ; Knibbe, CA; van Dongen, EP; van Ramshorst, B; Wiezer, RJ, 2015) |
| "Our current dosing practice of 40 mg SC for individuals with a BMI ≤50 kg/m(2) and 60 mg for individuals with a BMI ≥50 kg/m(2) resulted in anti-factor Xa activity that was sufficient for adequate thromboprophylaxis in adolescent bariatric surgical patients." | 2.80 | Use of Enoxaparin in Obese Adolescents During Bariatric Surgery--a Pilot Study. ( Mushtaq, A; Nadler, EP; van den Anker, JN; Vaughns, JD; Ziesenitz, VC, 2015) |
| "Body weight is a better predictor of anti-Xa levels compared to lean body weight." | 2.80 | Fixed-dose enoxaparin after bariatric surgery: the influence of body weight on peak anti-Xa levels. ( Brandjes, DP; Celik, F; Gerdes, VE; Hooijberg, JH; Huitema, AD; van de Laar, AW, 2015) |
| " We prospectively compared three enoxaparin dosing regimens for the achievement of goal peak anti-Factor Xa levels in medically ill patients (n 5 31) with extreme obesity (body mass index (BMI) ‡ 40 kg/m2)." | 2.77 | Prospective comparison of three enoxaparin dosing regimens to achieve target anti-factor Xa levels in hospitalized, medically ill patients with extreme obesity. ( Freeman, A; Horner, T; Pendleton, RC; Rondina, MT, 2012) |
| "Our purpose was to describe anti-Xa levels, dosage requirements, and complications associated with enoxaparin treatment doses in patients with morbid obesity." | 2.76 | Evaluation of therapeutic anticoagulation with enoxaparin and associated anti-Xa monitoring in patients with morbid obesity: a case series. ( Deal, EN; Hollands, JM; Reichley, RM; Riney, JN; Skrupky, LP; Smith, JR, 2011) |
| " During the preoperative dosing phase, parnaparin dose-dependently prolonged APTT, with the 6400 IU dose significantly prolonging APTT versus the lower doses." | 2.73 | Prophylaxis of thromboembolism in bariatric surgery with parnaparin. ( Cuocolo, A; De Caterina, M; Ferrari, P; Forestieri, P; Formato, A; Pilone, V; Quarto, G; Ruocco, A, 2007) |
| " In morbidity obese patients, the limited number of comparative trials are too sparse to allow a consensus on the effective dose and dosing schedule." | 2.70 | Prophylaxis of venous thromboembolism using two different doses of low-molecular-weight heparin (nadroparin) in bariatric surgery: a prospective randomized trial. ( Dimitrakopoulos, A; Kalfarentzos, F; Karamesini, M; Kehagias, I; Maniati, A; Stavropoulou, F; Yarmenitis, S, 2001) |
| " capped (< 1 mg/kg) enoxaparin dosing regimen." | 1.91 | Management of venous thromboembolism in morbidly obese patients: a 10-year review. ( Donarelli, C; Ho, P; Khattak, Z; Kwok, A; Lai, J; Lim, HY; Lui, B; Wee, B, 2023) |
| " VTE prophylaxis with weight-based enoxaparin dosing may be more effective than the standard dosing regimen for overweight and obese patients; however, weight-based dosing is not practiced routinely." | 1.91 | Evaluating Adequacy of VTE Prophylaxis Dosing with Enoxaparin for Overweight and Obese Patients on an Orthopedic-Medical Trauma Comanagement Service. ( Dailey, H; Jovin, F; Perrin, A; Sheth, H; Smith, R; Snyder, V, 2023) |
| "Anti-Xa-guided enoxaparin dosing for VTE prophylaxis in neurosurgical patients may help prevent major bleeding." | 1.72 | Supraprophylactic Anti-Factor Xa Levels Are Associated with Major Bleeding in Neurosurgery Patients Receiving Prophylactic Enoxaparin. ( Cua, S; May, CC; Powers, CJ; Smetana, KS, 2022) |
| "Individual enoxaparin dosage regimens for men and women do not seem to be required." | 1.72 | Comparison of Anti-factor Xa Levels in Female and Male Patients with Obesity After Enoxaparin Application for Thromboprophylaxis. ( Duprée, A; Izbicki, J; Lautenbach, A; Mann, O; von Kroge, P; Wagner, J; Wolter, S; Wruck, H, 2022) |
| " Various prophylaxis dosing strategies have been investigated." | 1.56 | Safety and Efficacy of High-Dose Unfractionated Heparin Versus High-Dose Enoxaparin for Venous Thromboembolism Prevention in Morbidly Obese Hospitalized Patients. ( Barber, A; Chen, SL; Jones, E; Mason, SW; Moll, S; Northam, K, 2020) |
| " More studies are needed on the prophylactic use and dosing of enoxaparin in patients undergoing LAGB procedures to provide high-level evidence." | 1.56 | Risk of venous thromboembolism, use of enoxaparin and clinical outcomes in obese patients undergoing laparoscopic adjustable gastric band surgery: A retrospective study. ( Curtain, C; Hussain, Z; Mirkazemi, C; Peterson, GM; Zaidi, STR, 2020) |
| "4 ml was started subcutaneously after the PCD was removed from the patient and the same dosage of nadroparin was given daily for 15 days following the bariatric operation." | 1.51 | A New Protocol for Venous Thromboembolism Prophylaxis in Bariatric Surgery. ( Abuoglu, HH; Müftüoğlu, MAT; Odabaşı, M, 2019) |
| "Patients with postoperative hemorrhage had a significantly lower MAP during the portion of the surgery in which the abdominal contents were inspected for leaks and bleeds." | 1.51 | Intraoperative Blood Pressure Lability Is Associated with Postoperative Hemorrhage after Uncomplicated Bariatric Surgery. ( Duffy, AJ; Ghiassi, S; Hubbard, MO; Nadzam, GS; Roberts, KE; Ying, LD, 2019) |
| "A personal history of malignancy and type 2 diabetes increase the risk of PMVT." | 1.48 | Assessing risk factors, presentation, and management of portomesenteric vein thrombosis after sleeve gastrectomy: a multicenter case-control study. ( Blanco, DG; Boyce, SG; De La Cruz-Munoz, N; Domkowski, P; Funes, DR; Ghanem, M; Jawad, MA; Menzo, EL; Moon, RC; Radecke, J; Rosenthal, R; Teixeira, AF; Young, MK, 2018) |
| "A case highlighting challenges with enoxaparin dosage and monitoring in obese patients is presented." | 1.46 | Treatment of suspected pulmonary embolism in a morbidly obese patient. ( Borgstadt, MB; Carlson, L; Heitlage, V, 2017) |
| "In the absence of sufficient data regarding clinical efficacy and safety of different dosing regimens both dosing regimens studied are reasonable choices for venous thromboembolic events prophylaxis after bariatric surgery." | 1.46 | Anti-factor Xa levels in patients undergoing laparoscopic sleeve gastrectomy: 2 different dosing regimens of enoxaparin. ( Eldar, SM; Gelikas, S; Lahat, G, 2017) |
| "Twelve additional patients experienced deep vein thrombosis and 6 had pulmonary embolism." | 1.46 | Abdominal thrombotic complications following bariatric surgery. ( Elazary, R; Kalish, Y; Rottenstreich, A, 2017) |
| "Variation exists in dosing and monitoring practices for therapeutic enoxaparin in the pregnant population." | 1.43 | Evaluation of therapeutic enoxaparin in a pregnant population at a tertiary hospital. ( Allen, J; Barras, M; Fagermo, N; Lust, K; Martin, JH; Petrie, S, 2016) |
| "To compare the adequacy of venous thromboembolism prophylaxis based on anti-Xa concentrations between weight-based enoxaparin dosing and body mass index (BMI)-stratified dosing in morbidly obese women after cesarean delivery." | 1.42 | Enoxaparin dosing after cesarean delivery in morbidly obese women. ( LaCoursiere, DY; Overcash, RT; Somers, AT, 2015) |
| "No bleeding was observed in any of the 99 patients." | 1.42 | Monitoring Enoxaparin with Antifactor Xa Levels in Obese Patients. ( Ballew, A; Duong, HN; Lee, YR; Vega, JA, 2015) |
| "Obesity increases the risk for venous thromboembolism (VTE), but whether high-dose thromboprophylaxis is safe and effective in morbidly obese inpatients is unknown." | 1.40 | Efficacy and safety of high-dose thromboprophylaxis in morbidly obese inpatients. ( Deal, EN; Gage, BF; Milligan, PE; Thoelke, MS; Wang, TF; Wong, CA, 2014) |
| " We investigated two different dosing regimens; fixed dose and weight-adjusted dose on the anticoagulant effects of the LMWH tinzaparin used for thromboprophylaxis in obese pregnant women." | 1.40 | Weight-adjusted LMWH prophylaxis provides more effective thrombin inhibition in morbidly obese pregnant women. ( Higgins, JR; Ismail, SK; Norris, L; O'Shea, S, 2014) |
| "Patients with morbid obesity were randomly selected among the total cohort and were matched with lower-weight controls (1:2 ratio) based on the presence of renal dysfunction (serum creatinine >1." | 1.39 | Assessment of bleeding events associated with short-duration therapeutic enoxaparin use in the morbidly obese. ( Deal, EN; Hagopian, JC; Hollands, JM; Riney, JN, 2013) |
| "Laparoscopic procedures for morbid obesity are becoming standard of care which, in experienced hands, has a very low mortality and morbidity." | 1.39 | Superior mesenteric vein thrombosis after laparoscopic sleeve gastrectomy. ( Ahmed, L; Pineda, L; Sarhan, M, 2013) |
| "A weight-based dosage range of enoxaparin 50-120 mg twice daily (median 60) was given to 23 patients." | 1.37 | Implementation of an enoxaparin protocol for venous thromboembolism prophylaxis in obese surgical intensive care unit patients. ( Barton, RG; Kimball, EJ; Ludwig, KP; Mone, M; Simons, HJ, 2011) |
| " In morbidly obese, medically-ill patients, use of weight-based enoxaparin dosed at 0." | 1.36 | Weight-based dosing of enoxaparin for VTE prophylaxis in morbidly obese, medically-Ill patients. ( Draper, L; Pendleton, RC; Rodgers, GM; Rondina, MT; Wheeler, M, 2010) |
| "Only cases with renal failure, morbid obesity or extreme age require anti-Xa monitoring to assure the therapeutic level achievement." | 1.36 | Stability of plasma anti-Xa activity in low-molecular-weight heparin monitoring. ( Akkawat, B; Juntiang, J; Rojnuckarin, P, 2010) |
| "These findings indicate that the 7,500 IU dalteparin dosage is appropriate for the majority of morbidly obese patients undergoing bariatric surgery." | 1.36 | Effect of prophylactic dalteparin on anti-factor Xa levels in morbidly obese patients after bariatric surgery. ( Picard, F; Simoneau, MD; Vachon, A, 2010) |
| "Enoxaparin significantly decreased deep venous thrombosis risk in patients undergoing circumferential abdominoplasty." | 1.35 | Thromboembolic risk assessment and the efficacy of enoxaparin prophylaxis in excisional body contouring surgery. ( Abtahi, F; Brown, SA; Farkas, JP; Hatef, DA; Kenkel, JM; Nguyen, MQ; Rohrich, RJ, 2008) |
| " Although VTE prophylaxis is recommended in bariatric surgery, data with regard to monitoring and appropriate dosing of low-molecular-weight heparin are limited." | 1.35 | Comparison of two low-molecular-weight heparin dosing regimens for patients undergoing laparoscopic bariatric surgery. ( Kuhl, DA; Lee, MD; Madan, AK; Simone, EP; Tichansky, DS, 2008) |
| "Limited data exist regarding efficacy and dosing of low-molecular-weight heparins, including enoxaparin, for morbidly obese patients." | 1.35 | Anti-Xa levels in bariatric surgery patients receiving prophylactic enoxaparin. ( Kuhl, DA; Lee, MD; Madan, AK; Rowan, BO; Tichansky, DS, 2008) |
| "This is because pulmonary embolism (PE) is a common cause of mortality postoperatively." | 1.35 | Post discharge prophylactic anticoagulation in gastric bypass patient-how safe? ( Asiyanbola, B; Ojo, P; Reinhold, R; Valin, E, 2008) |
| "Low-molecular-weight heparins are effective as initial therapy for pulmonary embolism (PE) in a weight-based dosing regimen up to known body weights of 160 kg." | 1.35 | Treatment of pulmonary embolism in an extremely obese patient. ( Diepstraten, J; Hackeng, CM; Knibbe, CA; Snijder, RJ; van Kralingen, S; van Ramshorst, B, 2009) |
| " In addition, we review the use of LMWH in renal insufficiency, dosing in obese patients,and the importance of sulfate content in the efficacy of protamine sulfate as a reversing agent for LMWH." | 1.32 | Incomplete reversal of enoxaparin toxicity by protamine: implications of renal insufficiency, obesity, and low molecular weight heparin sulfate content. ( Chawla, LS; Moore, G; Seneff, MG, 2004) |
| " All patients received a multi-modality DVT prophylaxis protocol that included: early ambulation, graduated compression stockings, intermittent pneumatic compression, and enoxaparin (LMWH) in two dosage groups." | 1.31 | A comparison of two different prophylactic dose regimens of low molecular weight heparin in bariatric surgery. ( Hoedema, RM; Scholten, DJ; Scholten, SE, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (1.69) | 18.2507 |
| 2000's | 15 (25.42) | 29.6817 |
| 2010's | 33 (55.93) | 24.3611 |
| 2020's | 10 (16.95) | 2.80 |
| Authors | Studies |
|---|---|
| Schijns, W | 1 |
| Deenen, MJ | 1 |
| Aarts, EO | 1 |
| Homan, J | 1 |
| Janssen, IMC | 1 |
| Berends, FJ | 1 |
| Kaasjager, KAH | 1 |
| Abuoglu, HH | 1 |
| Müftüoğlu, MAT | 1 |
| Odabaşı, M | 1 |
| Diepstraten, J | 2 |
| Janssen, EJ | 1 |
| Hackeng, CM | 2 |
| van Dongen, EP | 1 |
| Wiezer, RJ | 1 |
| van Ramshorst, B | 2 |
| Knibbe, CA | 2 |
| Lavrik, AS | 2 |
| Tyvonchuk, AS | 2 |
| Bubalo, AF | 2 |
| Zgonnik, AIu | 1 |
| Kalfarentzos, F | 1 |
| Stavropoulou, F | 1 |
| Yarmenitis, S | 1 |
| Kehagias, I | 1 |
| Karamesini, M | 1 |
| Dimitrakopoulos, A | 1 |
| Maniati, A | 1 |
| Imberti, D | 1 |
| Baldini, E | 1 |
| Pierfranceschi, MG | 1 |
| Nicolini, A | 1 |
| Cartelli, C | 1 |
| De Paoli, M | 1 |
| Boni, M | 1 |
| Filippucci, E | 1 |
| Cariani, S | 1 |
| Bottani, G | 1 |
| Forestieri, P | 1 |
| Quarto, G | 1 |
| De Caterina, M | 1 |
| Cuocolo, A | 1 |
| Pilone, V | 1 |
| Formato, A | 1 |
| Ruocco, A | 1 |
| Ferrari, P | 1 |
| Muñoz-Atienza, V | 1 |
| Gil-Rendo, A | 1 |
| Amo-Salas, M | 1 |
| Núñez-Guerrero, P | 1 |
| Martín-Fernández, J | 1 |
| May, CC | 1 |
| Cua, S | 1 |
| Smetana, KS | 1 |
| Powers, CJ | 1 |
| Wagner, J | 1 |
| Wruck, H | 1 |
| Lautenbach, A | 1 |
| von Kroge, P | 1 |
| Wolter, S | 1 |
| Mann, O | 1 |
| Izbicki, J | 1 |
| Duprée, A | 1 |
| Wee, B | 2 |
| Lui, B | 2 |
| Lai, J | 2 |
| Khattak, Z | 2 |
| Kwok, A | 2 |
| Donarelli, C | 2 |
| Ho, P | 2 |
| Lim, HY | 2 |
| Perrin, A | 1 |
| Sheth, H | 1 |
| Snyder, V | 1 |
| Dailey, H | 1 |
| Jovin, F | 1 |
| Smith, R | 1 |
| Reiter, AJ | 1 |
| Prinz, J | 1 |
| Li, Y | 1 |
| Nagle, AP | 1 |
| Hungness, ES | 1 |
| Teitelbaum, EN | 1 |
| Mason, SW | 1 |
| Barber, A | 1 |
| Jones, E | 1 |
| Chen, SL | 1 |
| Moll, S | 1 |
| Northam, K | 1 |
| Lee, YR | 2 |
| van Oosterom, N | 1 |
| Winckel, K | 1 |
| Barras, M | 2 |
| Hussain, Z | 1 |
| Peterson, GM | 1 |
| Mirkazemi, C | 1 |
| Curtain, C | 1 |
| Zaidi, STR | 1 |
| Abdelsalam, AM | 1 |
| ElAnsary, AMSE | 1 |
| Salman, MA | 1 |
| Nassef, SA | 1 |
| Elfergany, HM | 1 |
| Aisha, HAA | 1 |
| Heitlage, V | 1 |
| Borgstadt, MB | 1 |
| Carlson, L | 1 |
| Gelikas, S | 1 |
| Eldar, SM | 1 |
| Lahat, G | 1 |
| Moon, RC | 1 |
| Ghanem, M | 1 |
| Teixeira, AF | 1 |
| De La Cruz-Munoz, N | 1 |
| Young, MK | 1 |
| Domkowski, P | 1 |
| Radecke, J | 1 |
| Boyce, SG | 1 |
| Rosenthal, R | 1 |
| Menzo, EL | 1 |
| Blanco, DG | 1 |
| Funes, DR | 1 |
| Jawad, MA | 1 |
| Curry, MA | 1 |
| LaFollette, JA | 1 |
| Alexander, BR | 1 |
| Evans, KS | 1 |
| Tran, RH | 1 |
| Kempton, CL | 1 |
| Brunetti, L | 1 |
| Wassef, A | 1 |
| Sadek, R | 1 |
| Deshpande, K | 1 |
| Ziegler, J | 1 |
| Na, SS | 1 |
| Riley, P | 1 |
| Kagan, L | 1 |
| Ying, LD | 1 |
| Duffy, AJ | 1 |
| Roberts, KE | 1 |
| Ghiassi, S | 1 |
| Hubbard, MO | 1 |
| Nadzam, GS | 1 |
| Pineda, L | 1 |
| Sarhan, M | 1 |
| Ahmed, L | 1 |
| Wang, TF | 1 |
| Milligan, PE | 1 |
| Wong, CA | 1 |
| Deal, EN | 3 |
| Thoelke, MS | 1 |
| Gage, BF | 1 |
| Hagopian, JC | 1 |
| Riney, JN | 2 |
| Hollands, JM | 2 |
| Lalama, JT | 1 |
| Feeney, ME | 1 |
| Vandiver, JW | 1 |
| Beavers, KD | 1 |
| Walter, LN | 1 |
| McClintic, JR | 1 |
| Celik, F | 1 |
| Huitema, AD | 1 |
| Hooijberg, JH | 1 |
| van de Laar, AW | 1 |
| Brandjes, DP | 1 |
| Gerdes, VE | 1 |
| Thompson-Moore, NR | 1 |
| Wanat, MA | 1 |
| Putney, DR | 1 |
| Liebl, PH | 1 |
| Chandler, WL | 1 |
| Muntz, JE | 1 |
| Mushtaq, A | 1 |
| Vaughns, JD | 1 |
| Ziesenitz, VC | 1 |
| Nadler, EP | 1 |
| van den Anker, JN | 1 |
| Holländer, SW | 1 |
| Sifft, A | 1 |
| Hess, S | 1 |
| Klingen, HJ | 1 |
| Djalali, P | 1 |
| Birk, D | 1 |
| Overcash, RT | 1 |
| Somers, AT | 1 |
| LaCoursiere, DY | 1 |
| Vega, JA | 1 |
| Duong, HN | 1 |
| Ballew, A | 1 |
| Andújar Mateos, A | 1 |
| Matoses Chirivella, C | 1 |
| Rodríguez Lucena, FJ | 1 |
| Navarro Ruiz, A | 1 |
| Petrie, S | 1 |
| Lust, K | 1 |
| Fagermo, N | 1 |
| Allen, J | 1 |
| Martin, JH | 1 |
| Rottenstreich, A | 1 |
| Elazary, R | 1 |
| Kalish, Y | 1 |
| Mazhar, F | 1 |
| Ahmed, Y | 1 |
| Hatef, DA | 1 |
| Kenkel, JM | 1 |
| Nguyen, MQ | 1 |
| Farkas, JP | 1 |
| Abtahi, F | 1 |
| Rohrich, RJ | 1 |
| Brown, SA | 1 |
| Simone, EP | 1 |
| Madan, AK | 2 |
| Tichansky, DS | 2 |
| Kuhl, DA | 2 |
| Lee, MD | 2 |
| Raftopoulos, I | 1 |
| Martindale, C | 1 |
| Cronin, A | 1 |
| Steinberg, J | 1 |
| Rondina, MT | 2 |
| Wheeler, M | 1 |
| Rodgers, GM | 1 |
| Draper, L | 1 |
| Pendleton, RC | 2 |
| Rojnuckarin, P | 1 |
| Akkawat, B | 1 |
| Juntiang, J | 1 |
| Skrupky, LP | 1 |
| Smith, JR | 1 |
| Reichley, RM | 1 |
| Ludwig, KP | 1 |
| Simons, HJ | 1 |
| Mone, M | 1 |
| Barton, RG | 1 |
| Kimball, EJ | 1 |
| Freeman, A | 1 |
| Horner, T | 1 |
| Pryor, HI | 1 |
| Singleton, A | 1 |
| Lin, E | 1 |
| Lin, P | 1 |
| Vaziri, K | 1 |
| Kim, KH | 1 |
| Lynfield, Y | 1 |
| Chawla, LS | 1 |
| Moore, G | 1 |
| Seneff, MG | 1 |
| Frezza, EE | 1 |
| Wachtel, MS | 1 |
| Rowan, BO | 1 |
| Ojo, P | 1 |
| Asiyanbola, B | 1 |
| Valin, E | 1 |
| Reinhold, R | 1 |
| Stetsenko, AP | 1 |
| Smorzhevskiĭ, VI | 1 |
| Komarov, AI | 1 |
| Scholten, DJ | 1 |
| Hoedema, RM | 1 |
| Scholten, SE | 1 |
| Simoneau, MD | 1 |
| Vachon, A | 1 |
| Picard, F | 1 |
| Walden, A | 1 |
| Levison, R | 1 |
| Singh, S | 1 |
| Keeling, D | 1 |
| Kuzin, MI | 1 |
| Kuzin, NM | 1 |
| Markov, NK | 1 |
| Leont'eva, MS | 1 |
| Gorbatov, OI | 1 |
| Romanov, MM | 1 |
| Shumbalina, LF | 1 |
| Nesterova, SG | 1 |
| Ismail, SK | 1 |
| Norris, L | 1 |
| O'Shea, S | 1 |
| Higgins, JR | 1 |
| van Kralingen, S | 1 |
| Snijder, RJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Peri-and Postoperative Subcutaneous Adipose Tissue Cefazolin Determination Using Microdialysis in Morbidly Obese and Non-obese Patients[NCT01309152] | 16 participants (Actual) | Observational | 2011-01-31 | Completed | |||
| Peri -and Postoperative Drug Therapy Schedules for Morbidly Obese Patients[NCT01097148] | Phase 4 | 20 participants (Actual) | Interventional | 2009-11-30 | Completed | ||
| Prophylactic Use of Enoxaparin in Morbidly Obese Adolescents During Bariatric Surgery[NCT01587781] | 12 participants (Actual) | Observational | 2011-11-30 | Completed | |||
| Weight Based Enoxaparin for Venous Thromboembolism Prophylaxis in Trauma Patients[NCT01916707] | Phase 4 | 1,200 participants (Anticipated) | Interventional | 2013-07-31 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
14 trials available for dalteparin and Morbid Obesity
| Article | Year |
|---|---|
Population pharmacodynamic model for low molecular weight heparin nadroparin in morbidly obese and non-obese patients using anti-Xa levels as endpoint.
Topics: Adult; Anticoagulants; Factor Xa Inhibitors; Female; Humans; Male; Middle Aged; Models, Biological; | 2015 |
Population pharmacodynamic model for low molecular weight heparin nadroparin in morbidly obese and non-obese patients using anti-Xa levels as endpoint.
Topics: Adult; Anticoagulants; Factor Xa Inhibitors; Female; Humans; Male; Middle Aged; Models, Biological; | 2015 |
Population pharmacodynamic model for low molecular weight heparin nadroparin in morbidly obese and non-obese patients using anti-Xa levels as endpoint.
Topics: Adult; Anticoagulants; Factor Xa Inhibitors; Female; Humans; Male; Middle Aged; Models, Biological; | 2015 |
Population pharmacodynamic model for low molecular weight heparin nadroparin in morbidly obese and non-obese patients using anti-Xa levels as endpoint.
Topics: Adult; Anticoagulants; Factor Xa Inhibitors; Female; Humans; Male; Middle Aged; Models, Biological; | 2015 |
[Prophylaxis of thromboembolic complications in bariatric surgery].
Topics: Adolescent; Adult; Aged; Anticoagulants; Bariatric Surgery; Humans; Middle Aged; Nadroparin; Obesity | 2007 |
Prophylaxis of venous thromboembolism using two different doses of low-molecular-weight heparin (nadroparin) in bariatric surgery: a prospective randomized trial.
Topics: Adult; Anastomosis, Roux-en-Y; Anticoagulants; Body Mass Index; Female; Gastric Bypass; Humans; Inje | 2001 |
Prophylaxis of venous thromboembolism with low molecular weight heparin in bariatric surgery: a prospective, randomised pilot study evaluating two doses of parnaparin (BAFLUX Study).
Topics: Adult; Anticoagulants; Bariatric Surgery; Dose-Response Relationship, Drug; Drug Administration Sche | 2014 |
Prophylaxis of thromboembolism in bariatric surgery with parnaparin.
Topics: Adult; Anticoagulants; Bariatric Surgery; Blood Coagulation Tests; Body Mass Index; Combined Modalit | 2007 |
Extended use of bemiparin as thromboprophylaxis during bariatric surgery: results of anti-factor Xa activity measurements.
Topics: Adult; Anticoagulants; Bariatric Surgery; Body Mass Index; Drug Administration Schedule; Factor Xa; | 2018 |
Adding a Preoperative Dose of LMWH may Decrease VTE Following Bariatric Surgery.
Topics: Adolescent; Adult; Anticoagulants; Bariatric Surgery; Chemoprevention; Enoxaparin; Female; Heparin, | 2021 |
Evaluation of Treatment-Dose Enoxaparin in Acutely Ill Morbidly Obese Patients at an Academic Medical Center: A Randomized Clinical Trial.
Topics: Academic Medical Centers; Anticoagulants; Enoxaparin; Female; Humans; Male; Middle Aged; Obesity, Mo | 2019 |
Fixed-dose enoxaparin after bariatric surgery: the influence of body weight on peak anti-Xa levels.
Topics: Adult; Anticoagulants; Bariatric Surgery; Body Weight; Dose-Response Relationship, Drug; Enoxaparin; | 2015 |
Evaluation and Pharmacokinetics of Treatment Dose Enoxaparin in Hospitalized Patients With Morbid Obesity.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Enoxaparin; Factor Xa | 2015 |
Use of Enoxaparin in Obese Adolescents During Bariatric Surgery--a Pilot Study.
Topics: Adolescent; Anticoagulants; Bariatric Surgery; Chemoprevention; Drug Administration Schedule; Enoxap | 2015 |
Identifying the Bariatric Patient at Risk for Pulmonary Embolism: Prospective Clinical Trial Using Duplex Sonography and Blood Screening.
Topics: Adult; Bariatric Surgery; Blood Chemical Analysis; Blood Coagulation Tests; Enoxaparin; Female; Huma | 2015 |
Evaluation of therapeutic anticoagulation with enoxaparin and associated anti-Xa monitoring in patients with morbid obesity: a case series.
Topics: Adult; Aged; Blood Coagulation Factor Inhibitors; Enoxaparin; Evaluation Studies as Topic; Factor Xa | 2011 |
Prospective comparison of three enoxaparin dosing regimens to achieve target anti-factor Xa levels in hospitalized, medically ill patients with extreme obesity.
Topics: Adult; Anticoagulants; Bed Rest; Blood Coagulation Tests; Body Mass Index; Cohort Studies; Dose-Resp | 2012 |
45 other studies available for dalteparin and Morbid Obesity
| Article | Year |
|---|---|
The Effect of Obesity on Anti-Xa Concentrations in Bariatric Patients.
Topics: Adult; Aged; Algorithms; Anticoagulants; Body Weight; Factor Xa Inhibitors; Female; Gastric Bypass; | 2018 |
A New Protocol for Venous Thromboembolism Prophylaxis in Bariatric Surgery.
Topics: Adolescent; Adult; Anticoagulants; Bariatric Surgery; Blood Transfusion; Clinical Protocols; Female; | 2019 |
Supraprophylactic Anti-Factor Xa Levels Are Associated with Major Bleeding in Neurosurgery Patients Receiving Prophylactic Enoxaparin.
Topics: Adult; Aged; Anticoagulants; Drug Monitoring; Enoxaparin; Factor Xa Inhibitors; Female; Hemorrhage; | 2022 |
Comparison of Anti-factor Xa Levels in Female and Male Patients with Obesity After Enoxaparin Application for Thromboprophylaxis.
Topics: Anticoagulants; Drug Administration Schedule; Enoxaparin; Factor Xa Inhibitors; Female; Humans; Male | 2022 |
Management of venous thromboembolism in morbidly obese patients: a 10-year review.
Topics: Administration, Oral; Anticoagulants; Enoxaparin; Hemorrhage; Humans; Obesity, Morbid; Retrospective | 2023 |
Management of venous thromboembolism in morbidly obese patients: a 10-year review.
Topics: Administration, Oral; Anticoagulants; Enoxaparin; Hemorrhage; Humans; Obesity, Morbid; Retrospective | 2023 |
Management of venous thromboembolism in morbidly obese patients: a 10-year review.
Topics: Administration, Oral; Anticoagulants; Enoxaparin; Hemorrhage; Humans; Obesity, Morbid; Retrospective | 2023 |
Management of venous thromboembolism in morbidly obese patients: a 10-year review.
Topics: Administration, Oral; Anticoagulants; Enoxaparin; Hemorrhage; Humans; Obesity, Morbid; Retrospective | 2023 |
Evaluating Adequacy of VTE Prophylaxis Dosing with Enoxaparin for Overweight and Obese Patients on an Orthopedic-Medical Trauma Comanagement Service.
Topics: Anticoagulants; Enoxaparin; Humans; Obesity, Morbid; Overweight; Pilot Projects; Prospective Studies | 2023 |
Increased bleeding risk with enoxaparin venothromboembolism prophylaxis compared with heparin in patients undergoing bariatric surgery.
Topics: Adult; Bariatric Surgery; Enoxaparin; Female; Fibrinolytic Agents; Gastrectomy; Gastric Bypass; Hepa | 2023 |
Safety and Efficacy of High-Dose Unfractionated Heparin Versus High-Dose Enoxaparin for Venous Thromboembolism Prevention in Morbidly Obese Hospitalized Patients.
Topics: Adult; Aged; Anticoagulants; Dose-Response Relationship, Drug; Enoxaparin; Female; Hemorrhage; Hepar | 2020 |
Response to Comment on: "Stratifying Therapeutic Enoxaparin Dose in Morbidly Obese Patients by BMI Class: A Retrospective Cohort Study".
Topics: Body Mass Index; Enoxaparin; Humans; Obesity, Morbid; Retrospective Studies; Venous Thromboembolism | 2020 |
Comment On: "Stratifying Therapeutic Enoxaparin Dose in Morbidly Obese Patients by BMI Class: A Retrospective Cohort Study".
Topics: Body Mass Index; Enoxaparin; Humans; Obesity, Morbid; Retrospective Studies; Venous Thromboembolism | 2020 |
Risk of venous thromboembolism, use of enoxaparin and clinical outcomes in obese patients undergoing laparoscopic adjustable gastric band surgery: A retrospective study.
Topics: Adolescent; Adult; Aged; Anticoagulants; Bariatric Surgery; Comorbidity; Enoxaparin; Female; Humans; | 2020 |
Treatment of suspected pulmonary embolism in a morbidly obese patient.
Topics: Anticoagulants; Drug Monitoring; Enoxaparin; Female; Humans; Obesity, Morbid; Pulmonary Embolism; Tr | 2017 |
Anti-factor Xa levels in patients undergoing laparoscopic sleeve gastrectomy: 2 different dosing regimens of enoxaparin.
Topics: Adult; Bariatric Surgery; Biomarkers; Case-Control Studies; Drug Administration Schedule; Enoxaparin | 2017 |
Assessing risk factors, presentation, and management of portomesenteric vein thrombosis after sleeve gastrectomy: a multicenter case-control study.
Topics: Adult; Aged; Anticoagulants; Bariatric Surgery; Drug Therapy, Combination; Enoxaparin; Epidemiologic | 2018 |
Anticoagulant activity of enoxaparin and unfractionated heparin for venous thromboembolism prophylaxis in obese patients undergoing sleeve gastrectomy.
Topics: Adult; Anticoagulants; Enoxaparin; Female; Gastrectomy; Humans; Male; Middle Aged; Obesity, Morbid; | 2019 |
Intraoperative Blood Pressure Lability Is Associated with Postoperative Hemorrhage after Uncomplicated Bariatric Surgery.
Topics: Adult; Aged; Bariatric Surgery; Blood Pressure; Blood Transfusion; Case-Control Studies; Drug Admini | 2019 |
Superior mesenteric vein thrombosis after laparoscopic sleeve gastrectomy.
Topics: Anticoagulants; Enoxaparin; Female; Gastrectomy; Humans; Laparoscopy; Mesenteric Vascular Occlusion; | 2013 |
Efficacy and safety of high-dose thromboprophylaxis in morbidly obese inpatients.
Topics: Aged; Anticoagulants; Body Mass Index; Enoxaparin; Female; Hemorrhage; Heparin; Humans; Male; Middle | 2014 |
Assessment of bleeding events associated with short-duration therapeutic enoxaparin use in the morbidly obese.
Topics: Academic Medical Centers; Adult; Anticoagulants; Enoxaparin; Female; Hemorrhage; Hospitalization; Hu | 2013 |
Assessing an enoxaparin dosing protocol in morbidly obese patients.
Topics: Adult; Aged; Aged, 80 and over; Body Mass Index; Enoxaparin; Factor Xa Inhibitors; Female; Hospitali | 2015 |
Enoxaparin dosing after cesarean delivery in morbidly obese women.
Topics: Adult; Anticoagulants; Body Mass Index; Body Weight; Cesarean Section; Drug Dosage Calculations; Dru | 2015 |
Monitoring Enoxaparin with Antifactor Xa Levels in Obese Patients.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Drug Monitoring; Enoxaparin; Factor Xa Inhibitors; F | 2015 |
[Enoxaparin dosage in extreme obesity by monitoring anti-Xa factor].
Topics: Anticoagulants; Enoxaparin; Factor Xa; Humans; Male; Middle Aged; Monitoring, Physiologic; Obesity, | 2016 |
Evaluation of therapeutic enoxaparin in a pregnant population at a tertiary hospital.
Topics: Adolescent; Adult; Anticoagulants; Dose-Response Relationship, Drug; Drug Monitoring; Enoxaparin; Fe | 2016 |
Abdominal thrombotic complications following bariatric surgery.
Topics: Abdomen; Adult; Anticoagulants; Bariatric Surgery; Drug Administration Schedule; Enoxaparin; Female; | 2017 |
Individualized dosing of enoxaparin in a morbidly obese patient by monitoring the anti-factor Xa.
Topics: Blood Coagulation; Blood Coagulation Tests; Body Mass Index; Drug Dosage Calculations; Drug Monitori | 2017 |
Thromboembolic risk assessment and the efficacy of enoxaparin prophylaxis in excisional body contouring surgery.
Topics: Adult; Anticoagulants; Enoxaparin; Female; Humans; Middle Aged; Obesity, Morbid; Plastic Surgery Pro | 2008 |
Comparison of two low-molecular-weight heparin dosing regimens for patients undergoing laparoscopic bariatric surgery.
Topics: Adult; Bariatric Surgery; Chi-Square Distribution; Enoxaparin; Female; Fibrinolytic Agents; Heparin, | 2008 |
The effect of extended post-discharge chemical thromboprophylaxis on venous thromboembolism rates after bariatric surgery: a prospective comparison trial.
Topics: Adolescent; Adult; Aged; Bariatric Surgery; Enoxaparin; Female; Fibrinolytic Agents; Humans; Inciden | 2008 |
Weight-based dosing of enoxaparin for VTE prophylaxis in morbidly obese, medically-Ill patients.
Topics: Adult; Aged; Anticoagulants; Body Mass Index; Body Weight; Drug Administration Schedule; Enoxaparin; | 2010 |
Stability of plasma anti-Xa activity in low-molecular-weight heparin monitoring.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Blood Preservation; Child; | 2010 |
Implementation of an enoxaparin protocol for venous thromboembolism prophylaxis in obese surgical intensive care unit patients.
Topics: Adolescent; Adult; Aged; Anticoagulants; Body Mass Index; Drug Administration Schedule; Enoxaparin; | 2011 |
Practice patterns in high-risk bariatric venous thromboembolism prophylaxis.
Topics: Anticoagulants; Bariatric Surgery; Body Mass Index; Enoxaparin; Health Care Surveys; Heparin; Humans | 2013 |
Enoxaparin-induced generalized exanthem.
Topics: Biopsy, Needle; Drug Eruptions; Enoxaparin; Exanthema; Female; Follow-Up Studies; Humans; Immunohist | 2003 |
Incomplete reversal of enoxaparin toxicity by protamine: implications of renal insufficiency, obesity, and low molecular weight heparin sulfate content.
Topics: Acute Kidney Injury; Anastomosis, Surgical; Anticoagulants; Cholecystectomy; Comorbidity; Enoxaparin | 2004 |
A simple venous thromboembolism prophylaxis protocol for patients undergoing bariatric surgery.
Topics: Anticoagulants; Bariatric Surgery; Body Mass Index; Enoxaparin; Hemorrhage; Heparin; Humans; Obesity | 2006 |
Anti-Xa levels in bariatric surgery patients receiving prophylactic enoxaparin.
Topics: Adult; Anticoagulants; Bariatric Surgery; Enoxaparin; Factor Xa; Female; Humans; Male; Middle Aged; | 2008 |
Post discharge prophylactic anticoagulation in gastric bypass patient-how safe?
Topics: Adult; Anticoagulants; Body Mass Index; Cohort Studies; Dose-Response Relationship, Drug; Drug Admin | 2008 |
[Application of clexane for prophylaxis of thromboembolic complications in surgery of morbid obesity].
Topics: Adult; Anticoagulants; Digestive System Surgical Procedures; Enoxaparin; Female; Humans; Male; Middl | 2001 |
A comparison of two different prophylactic dose regimens of low molecular weight heparin in bariatric surgery.
Topics: Adult; Anticoagulants; Enoxaparin; Female; Humans; Male; Obesity, Morbid; Risk Factors; Venous Throm | 2002 |
Effect of prophylactic dalteparin on anti-factor Xa levels in morbidly obese patients after bariatric surgery.
Topics: Adult; Anticoagulants; Biliopancreatic Diversion; Chemoprevention; Dalteparin; Factor Xa; Female; Hu | 2010 |
A case of fatal pulmonary embolism raising questions about the dosing regimen for dalteparin in the very obese.
Topics: Anticoagulants; Dalteparin; Drug Administration Schedule; Fatal Outcome; Humans; Male; Middle Aged; | 2008 |
[Effect of fragmin, a low-molecular heparin, on hemostasis in patients with alimentary-constitutional obesity].
Topics: Adult; Body Constitution; Dalteparin; Female; Hemostasis; Heparin; Humans; Male; Middle Aged; Obesit | 1993 |
Weight-adjusted LMWH prophylaxis provides more effective thrombin inhibition in morbidly obese pregnant women.
Topics: Adult; Body Weight; Cohort Studies; Female; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Huma | 2014 |
Treatment of pulmonary embolism in an extremely obese patient.
Topics: Acenocoumarol; Anticoagulants; Drug Dosage Calculations; Drug Monitoring; Factor Xa; Factor Xa Inhib | 2009 |